Kitamura H, Kameda Y, Nakamura N, Nakatani Y, Inayama Y, Iida M, Noda K, Ogawa N, Shibagaki T, Kanisawa M
Department of Pathology, Yokohama City University, School of Medicine, Japan.
Am J Pathol. 1995 Apr;146(4):876-87.
To elucidate the pathogenesis of bronchioloalveolar lung carcinoma (BAC), we evaluated the lesion size, growth fraction, and p53 overexpression of atypical adenomatous hyperplasia (AAH) and early stage BAC. AAH was classified as showing low grade or high grade atypia. AAH-like carcinoma, presumably very early stage BAC, was distinguished from AAH in that it exhibited remarkable atypia suggestive of malignant potential and from overt BAC in that it lacked unequivocal malignant features, including invasive/destructive growth. The growth fraction was determined immunohistochemically in terms of the Ki-67 labeling index. The overexpression of p53 was evaluated by assessing the nuclear accumulation of immunoreactive p53 protein. Both the lesion size and the growth fraction increased from low grade AAH, to high grade AAH, to AAH-like carcinoma, and to overt adenocarcinoma. The overexpression of p53 in AAH-like carcinoma was similar to that in overt adenocarcinoma and was more frequent than that in AAH. Our findings indicate that AAH, AAH-like carcinoma, and overt BAC represent different categories, although the cellular events occurring in these lesions presumably represent a continuous spectrum of the changes that are reflected in the cytomorphology and lesion size. The findings here suggest that AAH and AAH-like carcinomas constitute a population of heterogeneous lesions representing different steps toward overt BAC.
为阐明细支气管肺泡肺癌(BAC)的发病机制,我们评估了非典型腺瘤样增生(AAH)和早期BAC的病变大小、生长分数及p53过表达情况。AAH分为低级别或高级别异型增生。AAH样癌,推测为极早期BAC,与AAH的区别在于其表现出提示恶性潜能的显著异型性,与明显的BAC的区别在于其缺乏明确的恶性特征,包括浸润性/破坏性生长。通过免疫组织化学方法根据Ki-67标记指数确定生长分数。通过评估免疫反应性p53蛋白的核内积聚来评价p53的过表达情况。病变大小和生长分数均从低级别AAH、高级别AAH、AAH样癌到明显的腺癌逐渐增加。AAH样癌中p53的过表达与明显腺癌相似,且比AAH中更常见。我们的研究结果表明,AAH、AAH样癌和明显的BAC代表不同类别,尽管这些病变中发生的细胞事件可能代表了在细胞形态学和病变大小中反映出的连续变化谱。此处的研究结果提示,AAH和AAH样癌构成了一组异质性病变,代表了向明显BAC发展的不同阶段。